Show simple item record

dc.contributor.author Gea Guiral, Joaquim
dc.contributor.author Enríquez Rodríguez, César Jessé
dc.contributor.author Agranovich, Bella
dc.contributor.author Pascual Guàrdia, Sergi, 1979-
dc.date.accessioned 2023-12-13T08:37:53Z
dc.date.available 2023-12-13T08:37:53Z
dc.date.issued 2023
dc.identifier.citation Gea J, Enríquez-Rodríguez CJ, Agranovich B, Pascual-Guardia S. Update on metabolomic findings in COPD patients. ERJ Open Res. 2023 Oct 30;9(5):00180-2023. DOI: 10.1183/23120541.00180-2023
dc.identifier.issn 2312-0541
dc.identifier.uri http://hdl.handle.net/10230/58522
dc.description.abstract COPD is a heterogeneous disorder that shows diverse clinical presentations (phenotypes and "treatable traits") and biological mechanisms (endotypes). This heterogeneity implies that to carry out a more personalised clinical management, it is necessary to classify each patient accurately. With this objective, and in addition to clinical features, it would be very useful to have well-defined biological markers. The search for these markers may either be done through more conventional laboratory and hypothesis-driven techniques or relatively blind high-throughput methods, with the omics approaches being suitable for the latter. Metabolomics is the science that studies biological processes through their metabolites, using various techniques such as gas and liquid chromatography, mass spectrometry and nuclear magnetic resonance. The most relevant metabolomics studies carried out in COPD highlight the importance of metabolites involved in pathways directly related to proteins (peptides and amino acids), nucleic acids (nitrogenous bases and nucleosides), and lipids and their derivatives (especially fatty acids, phospholipids, ceramides and eicosanoids). These findings indicate the relevance of inflammatory-immune processes, oxidative stress, increased catabolism and alterations in the energy production. However, some specific findings have also been reported for different COPD phenotypes, demographic characteristics of the patients, disease progression profiles, exacerbations, systemic manifestations and even diverse treatments. Unfortunately, the studies carried out to date have some limitations and shortcomings and there is still a need to define clear metabolomic profiles with clinical utility for the management of COPD and its implicit heterogeneity.
dc.format.mimetype application/pdf
dc.language.iso eng
dc.publisher European Respiratory Society
dc.relation.ispartof ERJ Open Res. 2023 Oct 30;9(5):00180-2023
dc.rights © The authors 2023. This version is distributed under the terms of the Creative Commons Attribution Non-Commercial Licence 4.0 (http://creativecommons.org/licenses/by-nc/4.0/). For commercial reproduction rights and permissions contact permissions@ersnet.org
dc.rights.uri http://creativecommons.org/licenses/by-nc/4.0/
dc.subject.other Metabolòmica
dc.subject.other Biologia molecular
dc.title Update on metabolomic findings in COPD patients
dc.type info:eu-repo/semantics/article
dc.identifier.doi http://dx.doi.org/10.1183/23120541.00180-2023
dc.rights.accessRights info:eu-repo/semantics/openAccess
dc.type.version info:eu-repo/semantics/publishedVersion

Thumbnail

This item appears in the following Collection(s)

Show simple item record

Search DSpace


Advanced Search

Browse

My Account

Statistics

In collaboration with Compliant to Partaking